Cargando…
MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer
Larynx cancer organ preservation treatments with chemo and radiotherapy have substantially improved laryngoesophageal dysfunction-free survival. However, both of them lead to a high incidence of acute and chronic toxicities and a significant number of patients relapse. To date, there is no evidence...
Autores principales: | de Miguel-Luken, María-José, Chaves-Conde, Manuel, de Miguel-Luken, Verónica, Muñoz-Galván, Sandra, López-Guerra, José Luis, Mateos, Juan C., Pachón, Jerónimo, Chinchón, David, Suarez, Vladimir, Carnero, Amancio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494962/ https://www.ncbi.nlm.nih.gov/pubmed/25788275 |
Ejemplares similares
-
Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival
por: de Miguel-Luken, María José, et al.
Publicado: (2016) -
MAP17, a ROS-dependent oncogene
por: Carnero, Amancio
Publicado: (2012) -
The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment
por: García-Heredia, José M., et al.
Publicado: (2017) -
Breast tumor cells promotes the horizontal propagation of EMT, stemness, and metastasis by transferring the MAP17 protein between subsets of neoplastic cells
por: García-Heredia, José Manuel, et al.
Publicado: (2020) -
Dr. Jekyll and Mr. Hyde: MAP17’s up-regulation, a crosspoint in cancer and inflammatory diseases
por: García-Heredia, José M., et al.
Publicado: (2018)